Developments in the mechanisms of allergy in 2018 through the eyes of Clinical and Experimental Allergy, Part I

In the second of two linked articles, we describe the development in clinical as described by Clinical & Experimental Allergy and other journals in 2019. Epidemiology, clinical allergy, asthma and rhinitis are all covered. In this article, we described the development in the field of allergy as described by Clinical and Experimental Allergy in 2019. Epidemiology, clinical allergy, asthma and rhinitis are all covered.

show abstract

“…In the related paper, we look at more mechanistic aspects. 88 We look forward to publishing more interesting observations in 2021.…”

Section: Con Clus Ionsmentioning

confidence: 99%

Developments allergy in 2019 through the eyes of Clinical and Experimental Allergy, Part II clinical allergy

Roberts

Almqvist

Boyle

et al. 2020

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…The year 2018 provided further advances in the field of allergy. 74 We look forward to publishing more interesting observations in 2020.…”

Section: Con Clus Ionsmentioning

confidence: 99%

Developments in the field of clinical allergy in 2018 through the eyes of Clinical and Experimental Allergy, Part II

Roberts

Almqvist

Boyle

et al. 2019

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

Chemokines in allergic conjunctivitis

Erdinest

London

Solomon

2020

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review Chemokines are a large group of low molecular weight cytokines that attract and activate leukocytes throughout the body and therefore have a key role in the framework of late-phase allergic responses. The purpose of this article is to provide an overview of the main chemokines involved in allergic conjunctivitis, their primary functions and their physiological roles, and therapies targeted at chemokines and their receptors for ocular allergic diseases. Recent findings In recent years, there have been considerable advances in the understanding of ocular pathophysiology of ocular surface inflammatory diseases including both allergic eye diseases and dry eye syndrome. Several therapies being developed for dry eye inflammation are recognized as possible therapies for ocular allergic diseases as there are often common chemokines involved in both disease spectra. Summary Chemokines represent an integral part of the late-phase cascade of ocular allergic inflammation. A deep understanding of specific chemokines and their interactions will help in targeting therapies to effectively manage ocular clinical findings and symptoms of allergic eye disease.

show abstract

Developments in the mechanisms of allergy in 2018 through the eyes of Clinical and Experimental Allergy, Part I

Abstract: In the first of two linked articles, we describe the development in the mechanisms underlying allergy as described by Clinical & Experimental Allergy and other journals in 2018. Experimental models of allergic disease, basic mechanisms and clinical mechanisms are all covered.

Cited by 3 publications

References 85 publications

Developments allergy in 2019 through the eyes of Clinical and Experimental Allergy, Part II clinical allergy

Developments allergy in 2019 through the eyes of Clinical and Experimental Allergy, Part II clinical allergy

Developments in the field of clinical allergy in 2018 through the eyes of Clinical and Experimental Allergy, Part II

Chemokines in allergic conjunctivitis

Contact Info

Product

Resources

About